GB713767A - Improvements relating to substituted quinazolones - Google Patents

Improvements relating to substituted quinazolones

Info

Publication number
GB713767A
GB713767A GB20948/51A GB2094851A GB713767A GB 713767 A GB713767 A GB 713767A GB 20948/51 A GB20948/51 A GB 20948/51A GB 2094851 A GB2094851 A GB 2094851A GB 713767 A GB713767 A GB 713767A
Authority
GB
United Kingdom
Prior art keywords
methoxy
acid
quinazolones
carbethoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB20948/51A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of GB713767A publication Critical patent/GB713767A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention comprises quinazolones of the general formula <FORM:0713767/IV (b)/1> wherein R represents at least one of the following: halogen atoms, alkoxy, aryloxy, aralkoxy hydroxy, aryl, alkyl, acyl and carboxyl radicals in one or more of the 5, 6, 7 and 8 positions; R1 represents a hydrogen atom or a hydroxy, alkoxy or aryloxy radical. The compounds may be prepared by subjecting quinazolones of the general formula <FORM:0713767/IV (b)/2> (wherein R11 represents -OC2H5; -O.CH2. C6H5; -O.C6H5; C6H5 or substituted phenyl radicals) to acid hydrolysis until the group -COR11 has been replaced by a hydrogen atom, and, where R1 is an alkoxy group, optionally further subjecting the resulting product to dealkylation. The acid hydrolysis is carried out using a strong inorganic acid, e.g. hydrohalic, sulphuric and phosphoric acids. In numerous detailed examples quinazolones of general formula II are refluxed in hydrochloric acid, evaporated to dryness and the products purified from ethanolic hydrogen chloride. For the preparation of compounds in which R1 is hydroxy, the corresponding methoxy derivative is refluxed in hydrobromic acid, evaporated to dryness and purified as above. The preparation is described of formula I compounds in which R1 is -OH or -OCH3 and R is 5-Cl; 6-Cl; 7-Cl; 8-Cl; 5-F; 5-CF3; 5-Br; 5-Me; 6-Me; 7-Me; 8-Me; 5-OMe; 6-OMe; 5-Cl, 8-MeO; 5-Cl, 6-Me; 6 : 8-di-Cl; or 5 : 6-di-Me. Quinazolones of general formula II are prepared by condensation of a 4-quinazolone of the general formula <FORM:0713767/IV (b)/3> with a substituted piperidine having the general formula <FORM:0713767/IV (b)/4> wherein X represents a halogen atom. In an example 6-chloro-4-quinazolone in sodium methoxide is treated with 1-carbethoxy-2-(g -bromoacetonyl)-3-methoxypiperidine to produce 3-[b - keto - g - (1 - carbethoxy - 3 - methoxy - 2-piperidyl) - propyl] - 6 - chloro - 4 - quinazolone. Other formula II quinazolones in which R and R1 represent the radicals listed above and R11 is a carbethoxy group are also described. The requisite 4-quinazolones are prepared from the corresponding anthranilic acids by fusion with formamide, a number of the necessary anthranilic acids being obtained from suitable isonitroso acetanilides by cyclization to the isatins followed by treatment with alkaline hydrogen peroxide. Detailed preparations of 8-chlor, 5-chloro - 8 - methoxy -, 5 - chloro -, 6 : 8 - dichloro-, 5 - bromo -, 5 - chloro - 6 - methyl -, 5 : 6 - dimethyl -, and 5 - trifluoromethyl - 4 - quinazolones are given. 5-Methoxy- and 5-fluoro-4-quinazolone are obtained by cyclization of 2-formylamino-6-methoxybenzamide and by diazotization of 5-amino-4-quinazolone respectively. The necessary substituted piperidines are prepared from 2-piperidones. In a detailed example, 3-chloro-3-carbethoxy-2-piperidone is converted to 3-methoxy-3-carbomethoxy-2-piperidone which upon treatment with acid and then benzyl chlorocarbonate yields 2-methoxy-5-carbobenzoxyaminovaleric acid. Conversion to the acid chloride followed by condensation with ethyl malonate furnishes ethyl (2-methoxy-5-carbobenzoxyamino valeryl) malonate which is hydrogenated to 3-methoxy piperidine-2-malonic ester, which upon hydrolysis and reaction with ethyl chlorocarbonate yields 1-carbethoxy-3-methoxy-2-piperidylacetic acid. This is converted via its acid chloride, treatment with diazomethane and finally hydrobromic acid into 1 - carbethoxy - 2 - [g - bromoacetonyl] - 3 - methoxypiperidine.
GB20948/51A 1950-09-09 1951-09-05 Improvements relating to substituted quinazolones Expired GB713767A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US713767XA 1950-09-09 1950-09-09

Publications (1)

Publication Number Publication Date
GB713767A true GB713767A (en) 1954-08-18

Family

ID=22100910

Family Applications (1)

Application Number Title Priority Date Filing Date
GB20948/51A Expired GB713767A (en) 1950-09-09 1951-09-05 Improvements relating to substituted quinazolones

Country Status (2)

Country Link
BE (1) BE505711A (en)
GB (1) GB713767A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2468368A1 (en) * 1979-08-23 1981-05-08 Hoechst Ag AGENT FOR THE TREATMENT OF QUINAZOLINONE THEILERIOSES
US4632926A (en) * 1982-07-06 1986-12-30 Vetem S.P.A. Quinazolinone derivatives which are active against coccidiosis
EP1737831A1 (en) * 2004-04-02 2007-01-03 Prana Biotechnology Limited Neurologically-active compounds
FR2921061A1 (en) * 2007-09-13 2009-03-20 Idealp Pharma Soc Par Actions Use of indolone compounds to treat malaria and inhibit the growth of the (non)resistant strains of Plasmodium falciparum, preferably one of the resistant strain to chloroquine
AU2005229161B2 (en) * 2004-04-02 2011-07-28 Prana Biotechnology Limited Neurologically-active compounds
KR101375074B1 (en) * 2004-04-02 2014-03-17 프라나 바이오테크놀로지 리미티드 Neurologically-active compounds
US9163018B2 (en) 2006-04-14 2015-10-20 Prana Biotechnology Inc. Method of treatment of age-related macular degeneration (AMD)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2468368A1 (en) * 1979-08-23 1981-05-08 Hoechst Ag AGENT FOR THE TREATMENT OF QUINAZOLINONE THEILERIOSES
US4632926A (en) * 1982-07-06 1986-12-30 Vetem S.P.A. Quinazolinone derivatives which are active against coccidiosis
EP1737831A1 (en) * 2004-04-02 2007-01-03 Prana Biotechnology Limited Neurologically-active compounds
JP2007530601A (en) * 2004-04-02 2007-11-01 プラナ バイオテクノロジー リミティッド Neurologically active compounds
EP1737831A4 (en) * 2004-04-02 2009-07-22 Prana Biotechnology Ltd Neurologically-active compounds
AU2005229161B2 (en) * 2004-04-02 2011-07-28 Prana Biotechnology Limited Neurologically-active compounds
US8084459B2 (en) 2004-04-02 2011-12-27 Prana Biotechnology Ltd Substituted quinazolinones for treating neurological conditions
JP4937111B2 (en) * 2004-04-02 2012-05-23 プラナ バイオテクノロジー リミティッド Neurologically active compounds
KR101375074B1 (en) * 2004-04-02 2014-03-17 프라나 바이오테크놀로지 리미티드 Neurologically-active compounds
US9163018B2 (en) 2006-04-14 2015-10-20 Prana Biotechnology Inc. Method of treatment of age-related macular degeneration (AMD)
FR2921061A1 (en) * 2007-09-13 2009-03-20 Idealp Pharma Soc Par Actions Use of indolone compounds to treat malaria and inhibit the growth of the (non)resistant strains of Plasmodium falciparum, preferably one of the resistant strain to chloroquine

Also Published As

Publication number Publication date
BE505711A (en)

Similar Documents

Publication Publication Date Title
SU795476A3 (en) Method of preparing derivatives of benzimidazole or their salts
US20030073582A1 (en) Fused heterocyclic dicarboxylic acid diamide derivatives or salts thereof, herbicide and method for using the same
Baker et al. An antimalarial alkaloid from Hydrangea. XIV. Synthesis of 5-, 6-, 7-, and 8-monosubstituted derivatives
GB713767A (en) Improvements relating to substituted quinazolones
CA2071224C (en) Quinoline derivatives, their production and use
DE2336718A1 (en) PROCESS FOR PREPARING SUBSTITUTED OXAZOLINONE (5) COMPOUNDS
DE2119730C3 (en)
DE2113343A1 (en) Indolo- (2,3) - quinolones - prepd by reaction of keto-indoles and anthranilates, followed by dehydration
Riegel et al. Preparation of 4-Quinolinols by the Ethyl Ethoxalylacetate Method1
Sreenivasulu et al. Search for physiologically active compounds: Part XXIII. Synthesis of 3-(3-pyridyl) and 3-(3-pyridyl)-4-methyl Coumarins
US3200130A (en) Derivatives of 1, 3, 4, 5-tetrahydro-benz[cd]indoles
DE2640652A1 (en) 3-SUBSTITUTED- (2-HYDROXY-3-AMINOPROPOXY) -1,2-BENZISOXAZOLE, METHOD FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
NO166536B (en) FLAMMETIC PHENOLIC FOAM AND PROCEDURE FOR ITS PREPARATION.
NO142403B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE ISOQINOLINES
DE855706C (en) Process for the production of coagulations of the 4,4&#39;-diaminostilbene
Elvidge et al. S 30. Gliotoxin. Part I. Synthesis of 2-thio-3-methylindolo-1′: 2′–1: 5-hydantoin and its identification as a degradation product of gliotoxin
Sóti et al. Synthesis of Vinca Alkaloids and Related Compounds. LXV. Preparation of 7-Methoxytryptamine
US3594392A (en) Dibenzo(b,e)thiepine-1,1-dioxides
DE2803541A1 (en) 1,2,3,4-Tetra:hydro-9H-pyrrolo-(3,4-b)-quinolin-9-one derivs. - with chromoglycate-like antiallergic and anti-asthmatic activity
DE19633805A1 (en) Optionally substituted 8-cyano-l-cyclopropyl-7- (2,8-diazabicyclo- [4.3.0] -nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and their derivatives
US2735852A (en) N nxch
DE856297C (en) Process for the production of 3- (2-oxy-phenyl) -pyrazole or its substitution products
US3347866A (en) 4-(indol-3-yl)-hexahydro-1h-azepines and their method of preparation
US2670359A (en) Treatment of steroid quaternary ammonium salts
DE859166C (en) Process for the preparation of benz (cd) indolines